Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents. Diabetes, obesity & metabolism Hood, K. K., Garcia-Willingham, N., Hanes, S., Tanenbaum, M. L., Ware, J., Boughton, C. K., Allen, J. M., Wilinska, M. E., Tauschmann, M., Denvir, L., Thankamony, A., Campbell, F., Wadwa, R. P., Buckingham, B. A., Davis, N., DiMeglio, L. A., Mauras, N., Besser, R. E., Ghatak, A., Weinzimer, S. A., Fox, D. S., Kanapka, L., Kollman, C., Sibayan, J., Beck, R. W., Hovorka, R., DAN05 Consortium 2022

Abstract

AIMS: To examine changes in the lived experience of type 1 diabetes after use of hybrid closed loop (CL), including the CamAPS FX CL system.MATERIALS & METHODS: The primary study was conducted as an open-label, single-period, randomized, parallel design contrasting CL versus insulin pump (with or without CGM). Participants were asked to complete patient-reported outcomes prior to starting CL and 3 and 6 months later. Surveys assessed diabetes distress, hypoglycemia concerns, and quality of life. Qualitative focus group data were collected at the completion of the study.RESULTS: In this sample of 98 youth (age range 6-18, mean age 12.7±2.8years) and their parents, CL use was not associated with psychosocial benefits overall. However, the subgroup (n=12) using the CamAPS FX system showed modest improvements in quality of life and parent distress, reinforced by both survey (p<0.05) and focus group responses. There were no negative effects of CL use reported by study participants.CONCLUSIONS: Closed loop use via the CamAPS FX system was associated with modest improvements in aspects of the lived experience of managing type 1 diabetes in youth and their families. Further refinements of the system may optimize the user experience. This article is protected by copyright. All rights reserved.

View details for DOI 10.1111/dom.14815

View details for PubMedID 35837984